Navigate Fool.com
Will KERX beat
the market?
Community Rating: 2 Stars: Unattractive

13.46 -0.46 (-3.30%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.97
Previous Close $13.92
Daily Range $13.43 - $14.17
52-Week Range $6.61 - $17.46
Market Cap $1.2B
P/E Ratio -24.00
Dividend (Yield) $0.00 (0.0%)
Volume 2,773,536
Average Daily Volume 3,543,315
Current FY EPS -$0.58

How do you think KERX
will perform against the market?

Top KERX Bull/Bear Pitches


zzlangerhans (< 20)
Submitted September 6, 2011

Keryx is another biotech which has struggled recently despite an absence of negative developments specific to the company. The company has already reported positive phase III efficacy data for kidney … More

2 Replies Reply Report this Post

supez2004 (< 20)
Submitted March 3, 2008

Phase 3 for sulodexide unlikely to impress ...

1 Replies Reply Report this Post

News & Commentary Rss Feed

Medicare Band-Aid Sends 1 Biotech Stock Surging

Keryx was the big winner in healthcare Thursday, up 17% in a single day due to both a successful drug and a success in Washington.

3 Humongous Health-Care Stocks This Week

Find out which health-care stocks sprang the most as spring began this week.

Why Keryx Biopharmaceuticals, Yongye International, and Five Below Are Today's 3 Best Stocks

Mixed economic data sacks the S&P 500 despite double-digit gains from Keryx Biopharmaceuticals, Yongye International, and Five Below.

Mid-Afternoon Market Update: Markets Turn Red as Dish Network Rises

Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis Shares Decline

Today's Biggest Health Care Stories: Keryx, Omeros, Alexion, and J&J

Keryx, Omeros, Alexion, and Johnson & Johnson could all loom large in health care headlines this morning. Here's all the news you need to know.

Use Options For a Chance To Buy KERX at a 41% Discount

3 Catalysts Biotech Investors Must Watch in 2014

Big money is riding on what happens with MannKind, Orexigen, and Keryx over the next few months.

Russell 2000 Rebalance May Bring Huge Buying in Key Stocks

Why Keryx Biopharmaceuticals, Inc. Shares Sank

Keryx shares move lower after announcing a share offering after the bell last night. Should investors shrug off today's downward move?

See More KERX News...





Keryx Biopharmaceuticals (KERX) Description

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Website: http://www.keryx.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks